 |
Video: What is a Stock Split?
|
 |
Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels. According to our AGLE split history records, AGLE has had 1 split. | |
 |

AGLE (AGLE) has 1 split in our AGLE split history database. The split for AGLE took place on September 08, 2023. This was a 1 for 25 reverse split, meaning for each 25 shares of AGLE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as AGLE conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the AGLE split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AGLE shares, starting with a $10,000 purchase of AGLE, presented on a split-history-adjusted basis factoring in the complete AGLE split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/08/2016 |
|
End date: |
11/27/2023 |
|
Start price/share: |
$299.75 |
|
End price/share: |
$12.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-95.99% |
|
Average Annual Total Return: |
-34.36% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$400.84 |
|
Years: |
7.64 |
|
|
 |
Date |
Ratio |
09/08/2023 | 1 for 25 |
|
 |